215 related articles for article (PubMed ID: 24146233)
81. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.
Herrmann R; Sturm M; Shaw K; Purtill D; Cooney J; Wright M; Phillips M; Cannell P
Int J Hematol; 2012 Feb; 95(2):182-8. PubMed ID: 22183779
[TBL] [Abstract][Full Text] [Related]
82. Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial.
Wang Y; Liu QF; Wu DP; Xu ZL; Han TT; Sun YQ; Huang F; Fan ZP; Xu N; Chen F; Zhao Y; Kong Y; Mo XD; Xu LP; Zhang XH; Liu KY; Huang XJ
BMC Med; 2024 Apr; 22(1):176. PubMed ID: 38664766
[TBL] [Abstract][Full Text] [Related]
83. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease.
Hoda D; Pidala J; Salgado-Vila N; Kim J; Perkins J; Bookout R; Field T; Perez L; Ayala E; Ochoa-Bayona JL; Raychaudhuri J; Alsina M; Greene J; Janssen W; Fernandez HF; Anasetti C; Kharfan-Dabaja MA
Bone Marrow Transplant; 2010 Aug; 45(8):1347-51. PubMed ID: 19966849
[TBL] [Abstract][Full Text] [Related]
84. Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial.
Bloom AI; Shapira MY; Or R; Sasson T; Resnick IB; Zilberman I; Verstandig A; Aker M; Slavin S; Muszkat M
Clin Ther; 2004 Mar; 26(3):407-14. PubMed ID: 15110133
[TBL] [Abstract][Full Text] [Related]
85. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
Khandelwal P; Lawrence J; Filipovich AH; Davies SM; Bleesing JJ; Jordan MB; Mehta P; Jodele S; Grimley MS; Kumar A; Myers K; Marsh RA
Pediatr Transplant; 2014 Feb; 18(1):94-102. PubMed ID: 24384050
[TBL] [Abstract][Full Text] [Related]
86. Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.
Girerd S; Renaud M; Guilhot J; Giraud C; Larchee R; Jollet I; Guilhot F
Bone Marrow Transplant; 2013 Sep; 48(9):1243-8. PubMed ID: 23503532
[TBL] [Abstract][Full Text] [Related]
87. Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation.
Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
Biol Blood Marrow Transplant; 2020 Feb; 26(2):351-357. PubMed ID: 31704470
[TBL] [Abstract][Full Text] [Related]
88. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
[TBL] [Abstract][Full Text] [Related]
89. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
Meng G; Wang J; Wang X; Wang Y; Wang Z
Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
[TBL] [Abstract][Full Text] [Related]
90. Prophylaxis regimens for GVHD: systematic review and meta-analysis.
Ram R; Gafter-Gvili A; Yeshurun M; Paul M; Raanani P; Shpilberg O
Bone Marrow Transplant; 2009 Apr; 43(8):643-53. PubMed ID: 18997826
[TBL] [Abstract][Full Text] [Related]
91. Photochemotherapy of Cutaneous Graft-versus-Host Disease May Reduce Concomitant Visceral Disease.
Feldreich N; Ringden O; Emtestam L; Omazic B
Dermatology; 2016; 232(4):453-63. PubMed ID: 27433980
[TBL] [Abstract][Full Text] [Related]
92. Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
Young JH; El Jurdi N; Rayes A; MacMillan ML; Holtan SG; Cao Q; Witte J; Arora M; Weisdorf DJ
Transplant Cell Ther; 2022 Aug; 28(8):509.e1-509.e11. PubMed ID: 35577324
[TBL] [Abstract][Full Text] [Related]
93. Role of folinic acid in methotrexate-based prophylaxis of graft-versus-host disease following hematopoietic stem cell transplantation.
AlJohani NI
Hematology; 2021 Dec; 26(1):620-627. PubMed ID: 34411497
[TBL] [Abstract][Full Text] [Related]
94. Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model.
Mielcarek M; Georges GE; Storb R
Biol Blood Marrow Transplant; 2006 Sep; 12(9):899-904. PubMed ID: 16920555
[TBL] [Abstract][Full Text] [Related]
95. Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease.
Isshiki K; Kamiya T; Endo A; Okamoto K; Osumi T; Kawai T; Arai K; Tomizawa D; Ohtsuka K; Nagahori M; Imai K; Kato M; Kanegane H
Int J Hematol; 2022 Apr; 115(4):590-594. PubMed ID: 34724153
[TBL] [Abstract][Full Text] [Related]
96. Mesenchymal Stem Cells as a Salvage Treatment for Severe Refractory Graft-vs-Host Disease in Children After Bone Marrow Transplantation.
Krasowska-Kwiecien A; Gozdzik J; Jarocha D; Wozniak M; Czogala W; Wiecha O; Skoczen S; Dluzniewska A; Majka M
Transplant Proc; 2019 Apr; 51(3):880-889. PubMed ID: 30979480
[TBL] [Abstract][Full Text] [Related]
97. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.
von Dalowski F; Kramer M; Wermke M; Wehner R; Röllig C; Alakel N; Stölzel F; Parmentier S; Sockel K; Krech M; Schmitz M; Platzbecker U; Schetelig J; Bornhäuser M; von Bonin M
Stem Cells; 2016 Feb; 34(2):357-66. PubMed ID: 26418955
[TBL] [Abstract][Full Text] [Related]
98. Tocilizumab for steroid refractory acute graft-versus-host disease.
Roddy JV; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC; Benson DM; Andritsos LA; Devine SM; Efebera YA
Leuk Lymphoma; 2016; 57(1):81-5. PubMed ID: 26140610
[TBL] [Abstract][Full Text] [Related]
99. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Przepiorka D; Luo L; Subramaniam S; Qiu J; Gudi R; Cunningham LC; Nie L; Leong R; Ma L; Sheth C; Deisseroth A; Goldberg KB; Blumenthal GM; Pazdur R
Oncologist; 2020 Feb; 25(2):e328-e334. PubMed ID: 32043777
[TBL] [Abstract][Full Text] [Related]
100. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Nassar A; Elgohary G; Elhassan T; Nurgat Z; Mohamed SY; Aljurf M
J Transplant; 2014; 2014():980301. PubMed ID: 25405023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
